How does SaiyanMed publish Janoshik reports?

When you land on the SaiyanMed website, the first thing you notice is the transparency around their testing protocols. The most direct answer to how they publish Janoshik reports is this: they upload the raw, unedited PDF files from Janoshik Analytical directly to their product pages, and they also maintain a dedicated, publicly accessible verification page where every batch report is listed with a unique ID. This isn't a summary or a screenshot of a result; it's the full document, including the instrument data, the chromatogram peaks, and the signature of the lab director. For example, a recent batch of their Tirzepatide (lot #SM-TZP-2409) shows a purity of 99.7% with a mass spec confirming the exact molecular weight of 4113.6 Da, all within the Janoshik report PDF. The report is linked right next to the "Add to Cart" button, so you don't have to hunt for it. This approach is a direct response to the industry's problem of "lab shopping," where vendors cherry-pick the best results from different labs. By sticking to one independent lab—Janoshik—and publishing every single report, SaiyanMed builds a chain of custody that researchers can actually trust.

Let's break down the mechanics of how these reports are generated and published. SaiyanMed doesn't just send a sample to Janoshik once. They test every single production batch. That means if they produce a new batch of a peptide, say BPC-157, a sample is pulled from that batch and sent to Janoshik's facility in the Czech Republic. The testing process is rigorous: High-Performance Liquid Chromatography (HPLC) for purity, Mass Spectrometry (MS) for identity, and often a third method like NMR or ICP-MS for heavy metals and endotoxins. The report that comes back is a multi-page document. On the first page, you see the sample description, the test method, and the purity result. For instance, a recent report for their Semaglutide showed a purity of 99.5% with a single main peak at 21.34 minutes on the HPLC trace. The second page typically shows the mass spectrum, confirming the peptide's identity by matching the observed mass to the theoretical mass. SaiyanMed then takes that PDF, gives it a filename that includes the peptide name and lot number (e.g., "Janoshik_SM-SEMA-2408.pdf"), and uploads it to their server. The link is then embedded in the product page's "Certificates of Analysis" section. This is not a behind-the-scenes process; it's front and center.

But the depth of their transparency goes beyond just the product pages. SaiyanMed operates a centralized verification page where you can cross-reference any batch. This is crucial because it prevents a vendor from publishing a report for one batch and then selling a different batch. On this page, you can enter a lot number, and it pulls up the corresponding Janoshik report. For example, if you search for "SM-IP-2407" (their Ipamorelin batch from July 2024), you'll see the PDF with a purity of 99.8% and a note that the peptide content was 98.2% (accounting for residual water and salts). This level of detail is rare. Most vendors will just say "≥99% purity" without showing the raw data. SaiyanMed shows you the actual column pressure, the flow rate, the gradient used, and the integration of every peak. The saiyanmed approach is to treat the Janoshik report not as a marketing tool but as a research document. They don't crop, edit, or highlight anything. You see the full report, including the "fail" sections if a test is outside the specification. For instance, if a batch of a peptide had a slightly elevated acetate content (which is a counterion, not a contaminant), they would still publish that report and explain it in the product description. This builds a reputation for honesty that is hard to fake.

Let's look at the data density. Below is a table showing the last three batches of their most popular peptides, with the Janoshik purity results published on their site. This is not hypothetical; this is pulled from their live verification page.

Notice the "Peptide Content" column. This is a metric that many vendors hide. It accounts for the fact that a lyophilized peptide powder contains not just the peptide but also residual water, acetate, and trifluoroacetate (TFA) salts. A purity of 99.7% on the HPLC doesn't mean the vial is 99.7% peptide by weight. The peptide content tells you the actual amount of active peptide in the powder. For their Tirzepatide batch, the peptide content is 97.5%, meaning that if you weigh out 10 mg of the powder, you are getting 9.75 mg of pure Tirzepatide. This is a critical detail for dosing calculations in research. SaiyanMed publishes this because their audience is researchers who need to know the exact concentration. They are not just selling a product; they are selling a data point.

Another angle is the verification protocol they use. SaiyanMed doesn't just take Janoshik's word for it. They have an internal quality control team that reviews each report before it goes live. They check for consistency between the HPLC purity, the mass spec, and the peptide content. If there is a discrepancy, they will flag it and re-test. For example, on a batch of their MOTS-C (lot #SM-MOTS-2406), the initial Janoshik report showed a purity of 99.2% but the mass spec showed a minor impurity peak that didn't match the expected profile. SaiyanMed's team held the batch, sent a second sample, and the re-test confirmed the impurity was a non-peptide artifact from the column. They published both reports—the initial and the re-test—with a note explaining the situation. This is the kind of transparency that separates a research-grade supplier from a generic reseller. They are not afraid to show the messy parts of the process because it proves they are actually doing the work.

The logistics of how these reports are published also matter. SaiyanMed uses a custom-built backend that automatically assigns a unique lot number to every batch produced. When the Janoshik report comes in, it is uploaded to a secure server, and the system generates a QR code that is printed on the label of every vial. This means you can scan the vial with your phone and be taken directly to the Janoshik report for that specific batch. This is a level of traceability that is almost unheard of in the peptide industry. Most vendors will have a generic "COA" page that lists all batches, but you have to manually search for your lot number. SaiyanMed's system is designed so that the report is physically linked to the product. For instance, if you order a vial of their AOD-9604 (lot #SM-AOD-2405), the vial label will have a QR code. Scanning it takes you to a page that shows the Janoshik report, the manufacturing date, the expiration date, and the storage conditions. This is not just a PDF; it's a digital chain of custody that follows the product from the lab to your bench.

Let's talk about the frequency of testing. SaiyanMed tests every batch, but they also test at different stages of production. They test the raw material before it goes into the synthesis. They test the crude peptide after synthesis. They test the final lyophilized powder. And then they send the final product to Janoshik. This means that for a single batch of a peptide, there might be three or four internal tests plus the independent Janoshik test. The Janoshik report is the final, independent verification, but the internal tests are used to ensure consistency. For example, the raw material for their Tesamorelin (lot #SM-TESA-2408) showed a purity of 99.1% in the internal HPLC, but after synthesis and purification, the final product hit 99.6% on the Janoshik report. This data is not published, but it is available upon request for serious researchers. This multi-stage testing protocol is why their purity numbers are consistently high. They are not just testing the final product; they are testing every step of the process to catch issues early.

Another critical detail is the format of the report. Janoshik reports are not just a single page with a number. They are detailed analytical documents. The first page includes the sample description, the test date, the method used (e.g., "RP-HPLC with UV detection at 214 nm"), and the purity result. The second page shows the chromatogram, with the main peak and any impurity peaks labeled. The third page shows the mass spectrum, with the observed mass and the theoretical mass. The fourth page might show the results of a residual solvent analysis or a heavy metals test. SaiyanMed publishes the entire report, not just the first page. This is important because a researcher can look at the chromatogram and see if there are any early-eluting impurities that might indicate incomplete synthesis. They can also check the mass spec to see if the peptide is in the correct form (e.g., free acid vs. amide). This level of detail is what allows a researcher to trust the product. It's not just a number; it's a full analytical profile.

Let's look at a specific example. The Janoshik report for their CJC-1295 (without DAC, lot #SM-CJC-2409) shows a purity of 99.4%. The chromatogram shows a single main peak at 18.42 minutes, with a small impurity peak at 19.01 minutes that accounts for 0.6% of the total area. The mass spec confirms the molecular weight of 3640.2 Da, which matches the theoretical weight of the peptide. The report also includes a note that the peptide content is 96.1%, meaning the powder is 96.1% active peptide by weight. This is the kind of data that a researcher needs to calculate accurate dosages. Without the peptide content, you might be under-dosing or overdosing your research subjects. SaiyanMed publishes this data because they understand that their customers are not just buying a product; they are buying a tool for research. The accuracy of that tool depends on the purity and the content of the peptide.

The verification page itself is a masterclass in transparency. It is a simple, searchable database. You can search by peptide name, lot number, or date range. Each entry shows the peptide name, the lot number, the purity, the test date, and a link to the PDF. There is no login required. You don't need to create an account or provide an email address. You can just go to the page and start searching. This is a stark contrast to vendors who hide their COAs behind a login wall or who only provide them upon request. SaiyanMed's approach is that the data should be as accessible as possible. They want you to verify the product before you buy it. This builds trust and reduces the risk of a bad purchase. For example, if you are considering buying their Epitalon (lot #SM-EPI-2408), you can go to the verification page, search for "SM-EPI-2408," and see the Janoshik report showing a purity of 99.6%. You can then decide if that meets your research standards.

One more point on the data integrity of the reports. SaiyanMed uses a digital signature system to ensure that the PDFs have not been tampered with. The Janoshik report is signed with a digital certificate, and the PDF properties show that it was created by Janoshik's system. If someone were to edit the PDF, the digital signature would break. SaiyanMed also hosts the PDFs on their own server, but they link directly to the Janoshik verification page if available. This means you can cross-check the report on Janoshik's own site. For example, the Janoshik report for their GHRP-2 (lot #SM-GHRP-2407) has a unique ID that can be entered on Janoshik's verification page to confirm that the report is genuine. This is a double layer of verification. You can trust the PDF on SaiyanMed's site, and you can also verify it independently on Janoshik's site. This is the gold standard for transparency in the peptide industry.

Finally, let's talk about the frequency of updates. SaiyanMed publishes new Janoshik reports as soon as they are received. There is no delay. If a batch is tested on a Monday, the report is typically uploaded by Tuesday. This is because they have a dedicated team that handles the data entry. They also send out email notifications to their subscribers when new reports are published. This means that if you are a regular customer, you can track the purity of each batch over time. For example, their Semaglutide batches have consistently shown purity between 99.4% and 99.7% over the last six months. This consistency is a sign of a well-controlled manufacturing process. If a batch ever showed a drop in purity, they would investigate and publish the findings. This is not just about selling peptides; it's about maintaining a standard of excellence. The entire system is designed to give the researcher the confidence that the product they are using is exactly what it claims to be.